The role of Medicare policy in fertility treatment decisions: perceptions of Australians considering, undertaking or who have undertaken medically assisted reproduction treatment
Lauren Jaensch A , Jessica A. Grieger B C and Melissa Oxlad A *A
B
C
Abstract
Fertility treatments offer the only pathway to parenthood for many people, including those with infertility, single people and those in same-sex relationships. We aimed to explore how current Medicare policy affects Australians’ fertility treatment decision-making.
Twenty-five people (22 females, 2 males, 1 agender/gender non-conforming) aged 26–54 who had used medically assisted reproduction treatments participated in semi-structured interviews. Data were analysed using reflexive thematic analysis.
We developed three themes. Theme 1: For those eligible, Medicare enhances accessibility – describes how Medicare influences affordability and, in turn, increases accessibility. Theme 2: Medicare alters treatment plans – demonstrates how Medicare influences who undertakes treatment, what treatment, when and how often. Theme 3: Medicare enables more treatment for some people – discusses how Medicare enables people to undertake more treatment than they could otherwise afford.
For eligible people, the current Medicare policy enhanced treatment accessibility and allowed them to undertake more treatment than they could have without financial assistance. However, Medicare policy also contributed to people altering their treatment plans, including who received treatment, the type, timing, frequency and amount of treatment. Given Medicare’s influence on fertility treatment decisions, our findings support calls for changes to Medicare eligibility to enable equitable access to fertility treatment and a pathway to parenthood for all Australians.
Keywords: assisted reproduction, cost, fertility treatment, in vitro fertilisation, infertility, Medicare, parenthood, treatment decision-making.
References
1 Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, Rienzi L, Sunde A, et al. The international glossary on infertility and fertility care, 2017. Fertil Steril 2017; 108(3): 393-406.
| Crossref | Google Scholar | PubMed |
2 Kushnir VA, Smith GD, Adashi EY. The future of IVF: The new normal in human reproduction. Reprod Sci 2022; 29(3): 849-856.
| Crossref | Google Scholar | PubMed |
3 Lazzari E, Potančoková M, Sobotka T, Gray E, Chambers GM. Projecting the contribution of assisted reproductive technology to completed cohort Fertility. Popul Res Policy Rev 2023; 42(1): 6.
| Crossref | Google Scholar | PubMed |
5 Raja NS, Russell CB, Moravek MB. Assisted reproductive technology: considerations for the nonheterosexual population and single parents. Fertil Steril 2022; 118(1): 47-53.
| Crossref | Google Scholar | PubMed |
6 Chambers GM, Hoang VP, Sullivan EA, Chapman MG, Ishihara O, Zegers-Hochschild F, Nygren KG, Adamson GD. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis. Fertil Steril 2014; 101(1): 191-198.
| Crossref | Google Scholar | PubMed |
7 Keller E, Botha W, Chambers GM. Does in vitro fertilization (IVF) treatment provide good value for money? A cost-benefit analysis. Front Glob Women’s Health 2023; 4: 971553.
| Crossref | Google Scholar | PubMed |
8 Harris K, Burley H, McLachlan R, Bowman M, Macaldowie A, Taylor K, Chapman M, Chambers GM. Socio-economic disparities in access to assisted reproductive technologies in Australia. Reprod Biomed Online 2016; 33(5): 575-584.
| Crossref | Google Scholar | PubMed |
9 Freed GL, Allen AR. Variation in outpatient consultant physician fees in Australia by specialty and state and territory. Med J Aust 2017; 206(4): 176-180.
| Crossref | Google Scholar | PubMed |
10 Westmead Fertility Centre. Treatment fees. Sydney: Westmead Fertility Centre; 2025. Available at https://westmeadfertilitycentre.com.au/treatment-fees/
11 Virtus Health. Costs of IVF. NSW: Virtus Health; 2025. Available at https://www.mivf.com.au/ivf-costs/costs-of-ivf
12 Lensen S, Hammarberg K, Polyakov A, Wilkinson J, Whyte S, Peate M, Hickey M. How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients. Hum Reprod 2021; 36(7): 1854-1861.
| Crossref | Google Scholar | PubMed |
13 Lensen S, Chen S, Goodman L, Rombauts L, Farquhar C, Hammarberg K. IVF add‐ons in Australia and New Zealand: A systematic assessment of IVF clinic websites. Aust N Z J Obstet Gynaecol 2021; 61(3): 430-438.
| Crossref | Google Scholar | PubMed |
14 Armstrong S, Atkinson M, MacKenzie J, Pacey A, Farquhar C. Add ons in the laboratory: hopeful, but not always helpful. Fertil Steril 2019; 112(6): 994-999.
| Crossref | Google Scholar | PubMed |
15 Kamath MS, Mascarenhas M, Franik S, Liu E, Sunkara SK. Clinical adjuncts in in vitro fertilization: a growing list. Fertil Steril 2019; 112(6): 978-986.
| Crossref | Google Scholar | PubMed |
16 The Senate. Ending the postcode lottery: Addressing barriers to sexual, maternity and reproductive healthcare in Australia. Canberra: Commonwealth of Australia Senate Printing Unit, Parliament House; 2023. Available at https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/ReproductiveHealthcare/Report#:~:text=Accessing%20maternity%20and%20termination%20care
17 Newman J, Kotevski D, Paul R, Chambers G. Assisted reproductive technology in Australia and New Zealand 2022 [report]. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales; 2024. Available at rtc.org.au/wp-content/uploads/2024/10/2024-09-assisted-reproductive-technology-in-australia-and-new-zealand-2022.pdf
18 Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. Hum Reprod Update 2012; 18(6): 652-669.
| Crossref | Google Scholar | PubMed |
19 Ghorbani M, Hoseini FS, Yunesian M, Salehin S, Keramat A, Nasiri S. A systematic review and meta-analysis on dropout of infertility treatments and related reasons/factors. J Obstet Gynaecol 2022; 42(6): 1642-1652.
| Crossref | Google Scholar | PubMed |
20 Tracy SJ. Qualitative quality: Eight “big-tent” criteria for excellent qualitative research. Qual Inq 2010; 16(10): 837-851.
| Crossref | Google Scholar |
22 International Federation of Fertility Societies’ Surveillance (IFFS). Global trends in reproductive policy and practice, 9th Edition. Glob Reprod Health 2022; 7(3): e58.
| Crossref | Google Scholar |
23 Kupka MS, Chambers GM, Dyer S, Zegers-Hochschild F, de Mouzon J, Ishihara O, Banker M, Jwa SC, et al. International Committee for Monitoring Assisted Reproductive Technology world report: Assisted reproductive technology, 2015 and 2016. Fertil Steril 2024; 122(5): 875-893.
| Crossref | Google Scholar | PubMed |
24 Australian and New Zealand Society for Reproductive Endocrinology and Infertility (ANZSREI) Executive Committee. Definition of Infertility: Consensus Statement. Australia: ANZSREI; 2024. Available at https://anzsrei.com/wp-content/uploads/2024/08/ANZSREI_Consensus-statement_extended-definition_02082024.pdf
25 Gallagher S, Attinger S, Sassano A, Sutton E, Kerridge I, Newson A, Farsides B, Hammarberg K, Hart R, Jackson E, Ledger W, Mayes C, Mills C, Norcross S, Norman RJ, Rombauts L, Waldby C, Yazdani A, Lipworth W. Medicine in the marketplace: clinician and patient views on commercial influences on assisted reproductive technology. Reprod Biomed Online 2024; 48(6): 103850.
| Crossref | Google Scholar | PubMed |
26 Chalmers K, Elshaug AG, Larkin S. First steps towards price transparency: comparability of online out-of-pocket tools from Australian private health funds. Aust Health Rev 2019; 44(3): 347-354.
| Crossref | Google Scholar | PubMed |
27 Sabanovic H, La Brooy C, Méndez SJ, Yong J, Scott A, Elshaug AG, Prang KH. “It’s not a one operation fits all”: A qualitative study exploring fee setting and participation in price transparency initiatives amongst medical specialists in the Australian private healthcare sector. Soc Sci Med 2023; 339: 116353.
| Crossref | Google Scholar | PubMed |
28 Yong J, Elshaug AG, Mendez SJ, Prang KH, Scott A. Sources of specialist physician fee variation: Evidence from Australian health insurance claims data. Health Policy 2024; 147: 105119.
| Crossref | Google Scholar | PubMed |
29 Ethics Committee of the American Society for Reproductive Medicine.. Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion. Fertil Steril 2019; 111(4): 659-663.
| Crossref | Google Scholar | PubMed |
